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Abstract
The B-cell CLL/lymphoma 2 (BCL2) gene family encodes pro- and anti-apoptotic proteins that are critical
regulators of programmed cell death. Higher levels of BCL2 expression in breast tumours have been shown to be
an independent prognostic factor for improved survival from breast cancer. The promoter single nucleotide
polymorphism (SNP) rs2279115 has been associated with both BCL2 expression and patient survival. The aim of
this study was to attempt to replicate these observations in a cohort of 1015 UK women with breast cancer, and
to compare genotype frequencies in cases and controls. In this study, 1015 breast cancer cases and 1034 control
subjects were genotyped for the rs2279115 SNP by 5’ nuclease PCR. Paraffin embedded tumour tissue for 342 case
subjects was assembled into tissue microarrays, and the level of expression of BCL2 was established by
immunohistochemistry. Kaplan Meier survival curves and Cox Proportional Hazards models were used to examine
the effect of genotype on patient survival. The effect of SNP genotype on tumour BCL2 protein levels and breast
cancer susceptibility was assessed by logistic regression. In this study higher BCL2 expression was significantly
associated with improved survival from breast cancer (p = 0.015), in keeping with previous reports. The SNP
rs2279115 was not found to be associated with tumour expression of BCL2, (p = 0.77), and neither was it
associated with case/control status (p = 0.25). There was no significant association between the SNP and overall
survival (p = 0.75). In conclusion, we found that higher tumour BCL2 expression is associated with improved
survival from breast cancer, in keeping with previous studies. However, in contrast to a previous report, the
promoter SNP rs2279115 was not associated with BCL2 expression or overall survival from breast cancer.
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Background
The balance between cell proliferation and levels of
apoptosis is frequently disrupted in tumours, with
tumorigenesis being promoted by both the loss of pro-
apoptotic signals and the gain of anti-apoptotic mechan-
isms (Hanahan & Weinberg 2000; Hanahan & Weinberg
2011). The BCL2 family of proteins plays a crucial role
in these processes, by integrating the complex pathways
incorporating pro- and anti-apoptotic signals at the
mitochondrial membrane (Tsujimoto 2002). The BCL-2
family can be categorised into anti-apoptotic and two
pro-apoptotic subgroups. The anti-apoptotic members
include BCL2 and Bcl-xL. The pro-apoptotic members
can be divided into a “multi-BH domain” group includ-
ing Bax and Bak and a BH3-only subgroup (Adams &
Cory 2002). However, BCL2 itself seems to act as both
an oncogene and a tumour suppressor gene in different
tumour types. For example, higher levels of tumour
BCL2 expression are associated with poor patient sur-
vival from chronic lymphocytic leukaemia (CLL), but
with improved survival from breast and colon cancer
(Faderl et al. 2002) (Buglioni et al. 1999) (Callagy et al.
2008).
The BCL2 gene consists of three exons and two pro-
moters; it is located on chromosome 18q21.3. The SNP
(rs2279115) is located in the inhibitory P2 promotor of
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the BCL2 gene (Park et al. 2004). The C allele in com-
parison to the A allele displayed significantly increased
inhibition of BCL2 promoter activity and binding of nu-
clear proteins (Nuckel et al. 2007). In keeping with these
findings BCL2 protein expression in B cells from CLL
patients carrying the AA genotype was significantly
increased compared with CC genotypes (Nuckel et al.
2007). This relationship was also demonstrated in rela-
tion to lymph node negative breast cancer in one previ-
ous study (Bachmann et al. 2007). In this study higher
expression of BCL2 was associated with the A-allele
(p = 0.044) and Kaplan-Meier survival analysis revealed
a significant association of the AA genotype with
improved survival (p = 0.030). This relationship has also
been demonstrated in oropharyngeal squamous cell car-
cinoma (Lehnerdt et al. 2009) where rs2279115 was sig-
nificantly associated with BCL2 expression (p = 0.008)
and with overall survival (p = 0.0247). This trend was
also demonstrated in renal cancer (Hirata et al. 2009).
Many studies have clearly demonstrated that increased
BCL2 expression is associated with improved outcome
from breast cancer (Yang et al. 2003) (Callagy et al. 2006)
(Callagy et al. 2008). (Dawson et al. 2010) (Ali et al.
2012). A multivariate analysis incorporating five pub-
lished studies from 11,212 breast cancer cases strongly
supported the independent prognostic significance of
BCL2 positivity with improved survival (Hazard Ratio
(HR) 0.76, 95% Confidence Interval (CI) 0.54-0.74),
p <0.001)(Dawson et al. 2010). In addition, expression of
BCL2 has been proven to be an independent indicator of
favourable prognosis for all types of early-stage breast
cancer (Callagy et al. 2008; Dawson et al. 2010).
The aim of this study was to use a cohort of breast
cancer cases, from the Sheffield Breast Cancer Study
(SBCS) to determine whether there is a relationship be-
tween the promoter SNP rs2279115 and tumour protein
levels of BCL2, and whether this corresponds to any dif-
ferences in patient survival. We also confirmed the
known association between high levels of tumour BCL2
and improved survival from breast cancer.
Materials and methods
Subjects
Between November 1998 and January 2005, 1274 women
with breast cancer and 1271 control subjects were en-
rolled in the SBCS. The design and methodology of this
case control study have been previously described (Rafii
et al. 2002) (Azmy et al. 2004). Briefly, all subjects were
residents of South Yorkshire, UK and were of European
descent. The breast cancer cases all had histopathologic-
ally confirmed breast cancer. The control subjects were
women aged between 50 and 65 attending the Sheffield
Mammography Screening Service between September
2000 and January 2004, whose mammograms showed no
evidence of breast lesions. The study was approved by
the South Sheffield Research Ethics Committee (SSREC/
98/137), and the DNA samples were collected with
informed consent from subjects for their use in genetic
studies of cancer. Paraffin-embedded tumour tissue was
requested from the relevant NHS Histopathology Arch-
ive for 342 of the subjects recruited above. Pathological
data (including tumour grade, morphology and lymph
node status) were obtained from medical pathology
records and validated (SSC). Immunohistochemical data
for the oestrogen receptor (ER), progesterone receptor
(PR), HER2 and cytokeratins 5/6 were available (Blows
et al. 2010). Data on all-cause mortality and survival was
obtained through the Trent Cancer Registry. Median
follow-up for breast cancer cases in September 2009 was
21.6 years including 220 deaths.
Determination of BCL2 rs2279115 genotype
Blood DNA samples were available from 1015 breast
cancer subjects and 1034 controls. These were geno-
typed for the SNP rs2279115 using a Taqman 5’ nuclease
PCR assay. The Probe sequence was as follows 5’-
CTCCCCAGGAGAGAGACAGGGGAGA[G/T]GGGA
CGATGAAGGAGCCGGGGACGG-3’, with the FAM
probe containing T and the VIC probe containing G.
The amplification reaction was performed in a final
volume of 5 μL, with 1.0 μL of genomic DNA (10 ng),
0.125 μL of TaqMan™ Genotyping Assay, 2.5 μL of
Taqman Genotyping Master Mix, and 2.375 μL of
water. The thermo- cycling conditions were as follows:
95°C for 10 min followed by 60 cycles of 92°C for 10 s
and 60°C for 1 min. Allelic discrimination was carried
out using the ABI 7900HT Sequence Detector (Life
Technologies) The overall genotype call rate was 96%
(980 cases and 981 controls successfully genotyped),
and duplicate concordance based on 133 duplicate
samples was 99.25%. The observed control genotype
frequencies were consistent with Hardy Weinberg
equilibrium (p = 0.76).
BCL2 immunohistochemistry
Tissue micro arrays were constructed from 342 archived
paraffin embedded tumour samples from the cancer co-
hort. Appropriate regions of tumour (judged by H.&.E
staining) were selected from the blocks and 0.6 mm tripli-
cate tissue cores were punched out from these regions
using a custom precision instrument (Beecher Instrument
Inc., Sun Prairie, US). These were then transferred into re-
cipient paraffin blocks in a specific orientation. 5 μm sec-
tions from the array blocks were dried, deparaffinised and
rehydrated before blocking endogenous peroxidase with a
solution of 2% hydrogen peroxide in methanol. The sec-
tions were then subjected to antigen retrieval by micro-
wave treatment in 10 Mm tri-sodium citrate. This was
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followed by a standard immunohistochemistical staining
procedure for BCL2 using a mouse monoclonal anti-
human BCL2 antibody (Dako Code M0887) at a dilution
of 1:50. The slides containing samples in triplicate were
assessed for BCL2 signal intensity (by two independent
observers (CJS and IWB) who were blinded to the genetic
and clinical data) and scored semi-quantitatively. Each
core on the microarray was given a score from zero (no
stain) to 3 (high staining) depending on the intensity of
the BLC2 staining from the tumour cells (Figure 1). The
highest of the three triplicate scores for each tissue sample
was used for statistical analysis. Agreement between the
two independent observers was good as demonstrated by
the Kappa statistic (k = 0.81).
Statistical analysis
All data was initially entered into a Microsoft Access
database and exported to STATA 9.2 for statistical ana-
lysis. Data analysis was restricted to the 980 case and
981 control subjects for whom SNP genotypes were
successfully called. Breast cancer epidemiological risk
factors were assessed by Mann Whitney U test for
continuous variables and by Pearson χ2 test for binary
variables. The relationship between BCL2 protein ex-
pression in tumours and SNP genotype, and that
between SNP genotype and case/control status was
assessed in a logistic regression model with AA as the
reference genotype. Kaplan-Meier survival functions and
Cox Proportional Hazards Regression models were used
to assess the effects of variables on overall survival,
using a left-truncated model to adjust for prevalent
cases (Azzato et al. 2009). Overall survival was calcu-
lated from the date of first diagnosis to confirmed death
or last known date of follow-up, up to a maximum of
10 years.
This project was designed and completed in accord-
ance with the REMARK reporting recommendations for
tumour MARKer prognostic studies (McShane et al.
2005).
Figure 1 Immunohistochemical evaluation of BCL2 protein expression in tissue microarrays of breast tumours. Tissue microarray cores
illustrating the BCL2 immunohistochemistry scoring system. Panels A-D show zero (score 0), low (score 1), moderate (score 2) and high (score 3)
BCL2 expression respectively.
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Results
Subject characteristics
Table 1 shows the epidemiological characteristics of the
cases and controls. There were no significant differences
in the percentage of post-menopausal women, age at
menarche or age at menopause between the cancer and
control groups. However, the women in the control
group were slightly younger compared to the cancer
group (median interquartile range (IQR) of 57 (53–61)
vs 59 (51–68); p =0.0004). Control subjects were
younger when first pregnant (median IQR of 23 (20–26)
vs 24 (21–27) in the cancer group (p = 1 × 10-6), and
had more children (median IQR of 2 (2–3) in the con-
trol group vs 2 (1–3) in the cancer group; p = 0.01). A
higher proportion of cases had a positive family history
of breast cancer compared to control subjects (14.5% vs
10.3%; p = 0.005).
The expected relationships were observed in case sub-
jects for overall survival with tumour grade (p = 1 × 10-5)
lymph node status (P = 3.2 × 10-10) (Figure 2).
Tumour BCL2 protein levels and overall survival
Following immunohistochemistry to detect BCL2 tumour
samples on tissue microarrays, the median intensity score
was 3 (range 0–3). Tumours with scores 0–1 were grouped
together (low tumour expression of BCL2; n = 35), and the
remaining two groups were score 2 (medium tumour ex-
pression of BCL2; n = 68) and score 3 (high tumour
expression; n = 145). In accordance with previous reports,
BCL2 tumour expression was significantly associated with
survival (p = 0.015; hazard ratio (95% confidence interval)
0.69 (0.51 to 0.93); Figure 3).
BCL2 expression level in relation to lymph node status,
grade, morphology, ER, PR, HER2, CK5/6 status and
rs2279115 genotype
Tumour BCL2 protein expression scores were grouped
into binary categories for comparison with standard
prognostic variables including tumour grade, nodal sta-
tus, ER, PR, HER2 and CK5/6 status (Table 2). The
binary categories were scores 0–1 being low expression
of BCL2 and scores 2–3 being high expression of
BCL2. High tumour BCL2 protein expression was asso-
ciated with lower grade of tumour (p = 4 × 10-9), pres-
ence of both oestrogen and progesterone receptor in
tumours (p = 1 × 10-14 and 5 × 10-5 respectively), and lack
of expression of CK5/6 (p = 0.002). There was no asso-
ciation with nodal involvement (p = 0.54), or morph-
ology (p = 0.68). A higher proportion of HER2 positive
tumours were BCL2-low but this was not statistically
significant (p = 0.07).
There was no association between the level of expres-
sion of BCL2 and rs2279115 genotype (OR (95% CI)
0.83 (0.38, 1.82) and 1.23 (0.37, 4.10) for AC and CC
genotypes, respectively, compared to AA genotype;
Table 3.
Effect of rs2279115 on breast cancer susceptibility and
overall survival
There was no difference in rs2279115 genotype frequen-
cies between cases and controls; OR (95% CI) were 0.93
(0.76, 1.14) and 0.81 (0.63, 1.04) respectively for AC and
CC genotypes compared to AA genotype (Table 4). Fur-
thermore the rs2279115 SNP was not associated with
overall survival, HR (95% CI) 1.03 (0.86, 1.24); p = 0.75
Table 1 Breast cancer risk factors in case and control subjects
Variable Controls Cases p values
Age N 981 980
Median (IQR) 57 (53–61) 59 (51–68) p = 0.0004a
Age at menarche N 972 962
Median (IQR) 13 (12–14) 13 (12–14) p = 0.83a
Age at menopause N 537 517
Median (IQR) 50 (47–52) 50(46–52) p = 0.62a
Age at first pregnancy N 878 807
Median (IQR) 23 (20–26) 24 (21–27) p = 0.000001a
Parity N 981 980
Median (IQR) 2 (2–3) 2(1–3) p = 0.01a
Menopausal status N 981 978
post 679 (69.2%) 653 (66.8%)
pre 302 (30.8%) 325 (33.2%) p = 0.25b
Family history of breast cancer N 981 980
Yes 101 (10.3%) 142 (14.5%)
No 880 (89.7%) 838 (85.5%) p = 0.005b
a Mann Whitney U test. b Pearson χ2 test. IQR: Inter-quartile range.
Positive family history was defined as the presence of at least one first degree relative with breast cancer.
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(Figure 4). In addition, no statistically significant associ-
ation was demonstrated between SNP genotype and sur-
vival in either lymph node negative or positive subjects
(Figure 5; p = 0.85 and 0.24 respectively).
Conclusion
The BCL2 family performs a cardinal role in the control
of apoptotic pathways, regulating both cell death and
cell survival mechanisms by altering mitochondrial
membrane permeability and controlling the release of
cytochrome c (Reed 1994). Unfavourable outcomes were
first reported in relation to inappropriate tumour BCL2
protein expression in follicular lymphoma as a result of
a chromosomal translocation t (14,18) (Tsujimoto et al.
1984). It was the break point in this translocation that
lead to the discovery of the BCL2 gene. The data pre-
sented here are consistent with previous reports that
show that in breast cancer, in contrast to non-Hodgkins
lymphoma, higher tumour protein expression of BCL2 is
associated with improved survival (Callagy et al. 2006)
Figure 2 Kaplan-Meier survival functions according to grade and lymph node status. A. Overall survival according to tumour grade, based
on 769 case subjects with total time at risk 5651.67 years. Numbers at risk at the end of the 10-year analysis period shown were 111 (grade 1),
203 (grade 2), 128 (grade 3). Hazard ratio (95% CI) 1.59 (1.30, 1.96), p = 1.0 × 10-5. B. Overall survival according to lymph node status, based on
786 case subjects with total time at risk 5808.75 years. Numbers at risk at the end of the 10-year analysis period were 316 (node negative) and
108 (node positive). Hazard ratio (95% CI) 2.59 (1.92, 3.48), p = 3.2 × 10-10.
Figure 3 Kaplan-Meier survival functions according to BCL2 protein expression levels. Overall survival based on 242 case subjects with
total time at risk 1846.10 years. 1: low expression (immunohistochemistry score zero or 1), 2: moderate expression (immunohistochemistry
score 2), 3: high expression (immunohistochemistry score 3). Numbers at risk at the end of the 10-year analysis period were 18 (low expression),
39 (moderate expression) and 97 (high expression). Hazard ratio (99.5% CI) 0.69 (0.51, 0.93), p = 0.015.
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(Callagy et al. 2008) (Dawson et al. 2010). Anti-apoptotic
BCL2 members act as repressors of apoptosis by block-
ing the release of cytochrome c, whereas pro-apoptotic
members act as promoters (Ghobrial et al. 2005). The
contrasting effect on survival of tumour BCL2 expres-
sion in breast cancer as opposed to non-Hodgkin lymph-
oma may well be due to the importance of the careful
equilibrium between tumour BCL2 protein expression
and other pro-apoptotic members such as Bax, rather
than on BCL2 tumour protein quantity alone (Reed
1997) (Cory et al. 2003). Unfortunately the exact mech-
anism that underpins this difference is not fully under-
stood. In vitro studies in a variety of different cell types
have found that high levels of BCL2 protein expression
in tumours can result in striking growth inhibition
(Pietenpol et al. 1994). In human breast cancer cell lines
there is an inverse correlation between the expression of
BCL2 and mutant p53 and that this relationship could
lead to down-regulation of BCL2 tumour protein expres-
sion (Haldar et al. 1994). Other studies have suggested a
function of BCL2 protein in lengthening the cell cycle
(O’Reilly et al. 1996) (Knowlton et al. 1998) (Lipponen
et al. 1995).
The relationship between tumour BCL2 protein ex-
pression and oestrogen has also been widely debated. It
has been suggested that the intrinsic and extrinsic path-
ways which make up the two main routes involved in
breast cancer cell apoptosis regulation, are both induced
when oestrogen binds to the oestrogen receptor. Both
pathways result in the activation of caspase leading fi-
nally to apoptosis (Lewis-Wambi & Jordan 2009). Leung
and Wang found that a breast cancer cell line treated
with the oestrogen 17β-oestradiol resulted in up-
regulation of BCL2 mRNA and protein, but down-
regulation of Bcl-x(L) mRNA and protein . They did not
find this result with other sex hormones. They specu-
lated that different members of the BCL2 family proteins
may be regulated through different pathways and that
these pathways may be modulated by 17β-oestradiol
(Leung & Wang 1999). Tumour BCL2 protein expres-
sion status has also been previously strongly associated
with PR and ER expression (Nadler et al. 2008) (Lee
et al. 1997). Our data are consistent with previous obser-
vations that BCL2 is a strong independent prognostic
marker for breast cancer survival (Dawson et al. 2010).
The SNP rs2279115 has been associated with BCL2
expression in CLL and breast cancer from node negative
patients (Bachmann et al. 2007). The study by Bachmann
et al. found that higher expression of BCL2 was asso-
ciated with the A-allele (P = 0.044) in lymph node
negative patients only. This also corresponded to an
improved survival in this group (HR (95% CI) 3.2
(1.03,9.93) p = 0.044). Lymph node negative patients
who were homozygous for the C allele had a higher
risk of death than AA homozygous patients, with
heterozygous women being intermediate in risk. In
the present data we found no association between
rs2279115 and tumour expression of BCL2 in the
whole cohort, or when results were subdivided into
Table 2 Level of BCL2 protein expression according to
lymph node status, tumour grade, morphology, ER, PR,
HER2 and CK5/6 status
Low BCL2 n
(%)
High BCL2 n
(%)
p valuea
Node status No nodal
Involvement
20 (64.5) 140 (70.0)
Nodal
Involvement
11 (35.5) 60 (30.0) 0.54
Grade 1 3 (8.8) 51 (24.9)
2 7 (20.6) 114 (55.6)
3 24 (70.6) 40 (19.5) 4x10-9
Morphology Ductal 28 (80.0) 159 (75.7)
Lobular 2 (5.7) 22 (10.5)
Other 5 (14.3) 29 (13.8) 0.68
ER status Negative 27 (79.4) 31 (15.3)
Positive 7 (20.6) 171 (84.7) 1x10-14
PR status Negative 20 (62.5) 53 (26.6)
Positive 12 (37.5) 146 (73.4) 5x10-5
HER2 status Negative 29 (82.9) 193 (92.3)
Positive 6 (17.1) 16 (7.7) 0.07
CK5/6 status Negative 23 (67.6) 180 (90.5)
Positive 11 (32.4) 19 (9.5) 0.0002
BCL2 immunohistochemistry scores were grouped into low (scores 0–1) and
high (scores 2–3) a Pearson χ2 test.
Table 3 Level of BCL2 protein expression of according to
rs2279115 genotype
Genotype Low BCL2
n (%)
High BCL2
n (%)
Odds
Ratio
95%
CI
p value
AA 12 (13.3) 78 (86.7) 1.00
AC 19 (15.6) 103 (84.4) 0.83 0.38 1.82 0.65
CC 4 (11.1) 32 (88.9) 1.23 0.37 4.10 0.74
TOTAL 35 (100) 213 (100.0)
BCL2 immunohistochemistry scores were grouped into low (scores 0–1) and
high (scores 2–3).
Table 4 Genotype frequencies for SNP rs2279115 in case
and control subjects
Genotype controls
n (%)
cases
n (%)
Odds
Ratio
95%
CI
p value
AA 290 (29.6) 314 (32.0) 1.00
AC 475 (48.4) 477 (48.7) 0.93 0.76 1.14 0.47
CC 216 (22.0) 189 (19.3) 0.81 0.63 1.04 0.098
TOTAL 981 (100) 980 (100.0)
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patient with lymph node positive or lymph node
negative disease. We also found no association with
survival for the different genotypes. Assuming a base-
line survival proportion of 0.84 in lymph node nega-
tive cases, our study would have been expected to
detect a hazard ratio of 3.2 between homozygous gen-
otypes (as was found by Bachmann et al. 2007), hav-
ing 80% power to detect hazard ratio of 1.8. However,
we are unable to exclude effects smaller than this. It
is possible that there may be genotypic effects on sur-
vival of similar or smaller magnitude to those of
BCL2 expression (Callagy et al. 2008; HR = 1.64); this
study is underpowered to detect these.
In conclusion we have no evidence to support the
SNP rs2279115 as a prognostic biomarker for breast
cancer patients. Higher BCL2 expression has been
Figure 4 Kaplan-Meier survival functions according to rs2279115 genotype. Overall survival based on 934 case subjects with total time at
risk 6765.43 years. Numbers at risk at the end of the 10-year analysis period were 158 (AA), 221 (AC), and 102 (CC). Hazard ratio (95% CI) 1.03
(0.86, 1.24), p = 0.75.
Figure 5 Kaplan-Meier survival functions in lymph node negative and positive subjects according to rs2279115 genotype. Overall
survival based on 786 subjects with total time at risk 5808.75 years. A shows lymph node negative subjects and B shows lymph node positive
subjects. Numbers at risk at the end of the 10-year analysis period were A: 103 (AA), 146 (AC), 79 (CC) and B: 38 (AA), 54 (AC), 18 (CC). Hazard
ratios (95% CI) for A were 0.97 (0.73, 1.30), p = 0.85 and for B were 1.20 (0.88, 1.64), p = 0.24.
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conclusively proven to correlate with improved survival
and further studies are required to explore its use as a
prognostic indicator.
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